vs
Massimo Group（MAMO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Massimo Group的1.4倍（$30.3M vs $21.0M），Massimo Group净利率更高（9.5% vs -221.3%，领先230.8%），REGENXBIO Inc.同比增速更快（43.0% vs 15.7%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -16.5%）
Massimo Dutti是一家西班牙高端服装零售商，主打开司米与羊毛制品，创立于1985年，现隶属于西班牙跨国集团Inditex。Inditex集团同时拥有Zara、Pull&Bear等知名服装品牌。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MAMO vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.0M
营收增速更快
RGNX
高出27.3%
15.7%
净利率更高
MAMO
高出230.8%
-221.3%
两年增速更快
RGNX
近两年复合增速
-16.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0M | $30.3M |
| 净利润 | $2.0M | $-67.1M |
| 毛利率 | 41.5% | — |
| 营业利润率 | 13.1% | -190.0% |
| 净利率 | 9.5% | -221.3% |
| 营收同比 | 15.7% | 43.0% |
| 净利润同比 | 215.0% | -31.2% |
| 每股收益（稀释后） | $0.05 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAMORGNX
| Q4 25 | $21.0M | $30.3M | ||
| Q3 25 | $17.0M | $29.7M | ||
| Q2 25 | $18.9M | $21.4M | ||
| Q1 25 | $14.9M | $89.0M | ||
| Q4 24 | $18.2M | $21.2M | ||
| Q3 24 | $25.6M | $24.2M | ||
| Q2 24 | $35.4M | $22.3M | ||
| Q1 24 | $30.2M | $15.6M |
净利润MAMORGNX
| Q4 25 | $2.0M | $-67.1M | ||
| Q3 25 | $1.5M | $-61.9M | ||
| Q2 25 | $77.7K | $-70.9M | ||
| Q1 25 | $-2.1M | $6.1M | ||
| Q4 24 | $-1.7M | $-51.2M | ||
| Q3 24 | $-2.5M | $-59.6M | ||
| Q2 24 | $2.8M | $-53.0M | ||
| Q1 24 | $3.2M | $-63.3M |
毛利率MAMORGNX
| Q4 25 | 41.5% | — | ||
| Q3 25 | 42.0% | — | ||
| Q2 25 | 36.3% | — | ||
| Q1 25 | 28.4% | — | ||
| Q4 24 | 19.6% | 70.2% | ||
| Q3 24 | 27.2% | 48.8% | ||
| Q2 24 | 32.5% | 52.5% | ||
| Q1 24 | 34.7% | 72.6% |
营业利润率MAMORGNX
| Q4 25 | 13.1% | -190.0% | ||
| Q3 25 | 10.5% | -176.3% | ||
| Q2 25 | 0.8% | -296.3% | ||
| Q1 25 | -18.2% | 13.6% | ||
| Q4 24 | -15.4% | -242.1% | ||
| Q3 24 | 1.2% | -256.6% | ||
| Q2 24 | 10.1% | -251.3% | ||
| Q1 24 | 13.2% | -408.8% |
净利率MAMORGNX
| Q4 25 | 9.5% | -221.3% | ||
| Q3 25 | 9.0% | -208.3% | ||
| Q2 25 | 0.4% | -331.8% | ||
| Q1 25 | -14.0% | 6.8% | ||
| Q4 24 | -9.5% | -241.3% | ||
| Q3 24 | -9.8% | -246.3% | ||
| Q2 24 | 8.0% | -237.7% | ||
| Q1 24 | 10.6% | -405.4% |
每股收益（稀释后）MAMORGNX
| Q4 25 | $0.05 | $-1.30 | ||
| Q3 25 | $0.04 | $-1.20 | ||
| Q2 25 | $0.00 | $-1.38 | ||
| Q1 25 | $-0.05 | $0.12 | ||
| Q4 24 | $-0.05 | $-0.99 | ||
| Q3 24 | $-0.06 | $-1.17 | ||
| Q2 24 | $0.07 | $-1.05 | ||
| Q1 24 | $0.08 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.8M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $23.7M | $102.7M |
| 总资产 | $51.4M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MAMORGNX
| Q4 25 | $5.8M | $230.1M | ||
| Q3 25 | $2.6M | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | $3.0M | $267.9M | ||
| Q4 24 | $10.2M | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益MAMORGNX
| Q4 25 | $23.7M | $102.7M | ||
| Q3 25 | $21.7M | $161.5M | ||
| Q2 25 | $20.2M | $213.7M | ||
| Q1 25 | $19.9M | $274.2M | ||
| Q4 24 | $21.7M | $259.7M | ||
| Q3 24 | $22.5M | $301.4M | ||
| Q2 24 | $24.7M | $348.3M | ||
| Q1 24 | $18.1M | $390.7M |
总资产MAMORGNX
| Q4 25 | $51.4M | $453.0M | ||
| Q3 25 | $44.4M | $525.2M | ||
| Q2 25 | $45.9M | $581.0M | ||
| Q1 25 | $46.4M | $490.9M | ||
| Q4 24 | $54.9M | $466.0M | ||
| Q3 24 | $57.1M | $519.1M | ||
| Q2 24 | $49.9M | $569.4M | ||
| Q1 24 | $47.3M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 2.01× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MAMORGNX
| Q4 25 | $4.0M | $-52.3M | ||
| Q3 25 | $633.2K | $-56.0M | ||
| Q2 25 | $-1.4M | $-49.3M | ||
| Q1 25 | $-3.3M | $33.6M | ||
| Q4 24 | $9.1M | $-31.6M | ||
| Q3 24 | $4.7M | $-40.5M | ||
| Q2 24 | $-6.5M | $-45.5M | ||
| Q1 24 | $-637.0K | $-55.5M |
自由现金流MAMORGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | $9.0M | $-32.7M | ||
| Q3 24 | $4.6M | $-40.9M | ||
| Q2 24 | $-6.7M | $-46.0M | ||
| Q1 24 | $-741.4K | $-56.0M |
自由现金流率MAMORGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | 49.7% | -154.2% | ||
| Q3 24 | 18.1% | -168.9% | ||
| Q2 24 | -19.0% | -206.2% | ||
| Q1 24 | -2.5% | -358.5% |
资本支出强度MAMORGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 0.2% | 5.1% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.7% | 2.1% | ||
| Q1 24 | 0.3% | 3.6% |
现金转化率MAMORGNX
| Q4 25 | 2.01× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | -17.92× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.30× | — | ||
| Q1 24 | -0.20× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAMO
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
